Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Massimo Gentile

Showing results (221-230 of 313) with videos related to

Pageof 32
Sort By:
Plos One|March 19, 2015
Insulin growth factor 1 receptor expression is associated with NOTCH1 mutation, trisomy 12 and aggressive clinical course in chronic lymphocytic leukaemiaFrancesco Maura, Laura Mosca, Sonia Fabris, et al.
American Journal of Hematology|July 24, 2019
Hematogenous extramedullary relapse in multiple myeloma - a multicenter retrospective study in 127 patientsIrit Avivi, Yael C Cohen, Anna Suska, et al.
British Journal of Haematology|July 3, 2026
Real-world effectiveness and safety of acalabrutinib in chronic lymphocytic leukaemia: Multicentre experienceAndrea Duminuco, Dario Leotta, Alessandro Allegra, et al.
Non-Coding RNA|September 23, 2024
MicroRNA Profiling as a Predictive Indicator for Time to First Treatment in Chronic Lymphocytic Leukemia: Insights from the O-CLL1 Prospective StudyEnnio Nano, Francesco Reggiani, Adriana Agnese Amaro, et al.
American Journal of Hematology|August 12, 2020
Younger patients with Waldenström Macroglobulinemia exhibit low risk profile and excellent outcomes in the era of immunotherapy and targeted therapiesMarzia Varettoni, Angela Ferrari, Anna M Frustaci, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 12, 2014
microRNAome expression in chronic lymphocytic leukemia: comparison with normal B-cell subsets and correlations with prognostic and clinical parametersMassimo Negrini, Giovanna Cutrona, Cristian Bassi, et al.
Leukemia & Lymphoma|February 5, 2015
Bendamustine and rituximab combination is safe and effective as salvage regimen in Waldenström macroglobulinemiaAlessandra Tedeschi, Paola Picardi, Simone Ferrero, et al.
Cancers|November 8, 2019
Lenalidomide Maintenance with or without Prednisone in Newly Diagnosed Myeloma Patients: A Pooled AnalysisFrancesca Bonello, Stefano Pulini, Stelvio Ballanti, et al.
Pharmaceuticals (Basel, Switzerland)|June 27, 2025
Correction: Sgherza et al. Efficacy and Safety of Isatuximab, Carfilzomib, and Dexamethasone (IsaKd) in Multiple Myeloma Patients at the First Relapse After Autologous Stem Cell Transplantation and Lenalidomide Maintenance: Results from the Multicenter, Real-Life AENEID Study. <i>Pharmaceuticals</i> 2025, <i>18</i>, 595Nicola Sgherza, Olga Battisti, Paola Curci, et al.
Leukemia & Lymphoma|April 11, 2015
Association between gene and miRNA expression profiles and stereotyped subset #4 B-cell receptor in chronic lymphocytic leukemiaFrancesco Maura, Giovanna Cutrona, Laura Mosca, et al.
Pageof 32

Showing results (221-230 of 313) with videos related to

Sort By:
Pageof 32
Plos One|March 19, 2015
Insulin growth factor 1 receptor expression is associated with NOTCH1 mutation, trisomy 12 and aggressive clinical course in chronic lymphocytic leukaemiaFrancesco Maura, Laura Mosca, Sonia Fabris, et al.
American Journal of Hematology|July 24, 2019
Hematogenous extramedullary relapse in multiple myeloma - a multicenter retrospective study in 127 patientsIrit Avivi, Yael C Cohen, Anna Suska, et al.
British Journal of Haematology|July 3, 2026
Real-world effectiveness and safety of acalabrutinib in chronic lymphocytic leukaemia: Multicentre experienceAndrea Duminuco, Dario Leotta, Alessandro Allegra, et al.
Non-Coding RNA|September 23, 2024
MicroRNA Profiling as a Predictive Indicator for Time to First Treatment in Chronic Lymphocytic Leukemia: Insights from the O-CLL1 Prospective StudyEnnio Nano, Francesco Reggiani, Adriana Agnese Amaro, et al.
American Journal of Hematology|August 12, 2020
Younger patients with Waldenström Macroglobulinemia exhibit low risk profile and excellent outcomes in the era of immunotherapy and targeted therapiesMarzia Varettoni, Angela Ferrari, Anna M Frustaci, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 12, 2014
microRNAome expression in chronic lymphocytic leukemia: comparison with normal B-cell subsets and correlations with prognostic and clinical parametersMassimo Negrini, Giovanna Cutrona, Cristian Bassi, et al.
Leukemia & Lymphoma|February 5, 2015
Bendamustine and rituximab combination is safe and effective as salvage regimen in Waldenström macroglobulinemiaAlessandra Tedeschi, Paola Picardi, Simone Ferrero, et al.
Cancers|November 8, 2019
Lenalidomide Maintenance with or without Prednisone in Newly Diagnosed Myeloma Patients: A Pooled AnalysisFrancesca Bonello, Stefano Pulini, Stelvio Ballanti, et al.
Pharmaceuticals (Basel, Switzerland)|June 27, 2025
Correction: Sgherza et al. Efficacy and Safety of Isatuximab, Carfilzomib, and Dexamethasone (IsaKd) in Multiple Myeloma Patients at the First Relapse After Autologous Stem Cell Transplantation and Lenalidomide Maintenance: Results from the Multicenter, Real-Life AENEID Study. <i>Pharmaceuticals</i> 2025, <i>18</i>, 595Nicola Sgherza, Olga Battisti, Paola Curci, et al.
Leukemia & Lymphoma|April 11, 2015
Association between gene and miRNA expression profiles and stereotyped subset #4 B-cell receptor in chronic lymphocytic leukemiaFrancesco Maura, Giovanna Cutrona, Laura Mosca, et al.
Pageof 32